Peyman Kabolizadeh, MD PhD

After completing his undergraduate degree in chemistry, Dr. Peyman Kabolizadeh was accepted into the combined MD/PhD program at Medical College of Virginia. He was then recruited to the Radiation Oncology residency program at University of Pittsburgh Medical Center, where he gained extensive experience in advanced techniques including Intensity-Modulated Radiation Therapy, Stereotactic Body Radiotherapy, and Stereotactic Radiosurgery (SBRT/SRS). Dr. Kabolizadeh then completed fellowship training in Proton Therapy at Harvard Medical School/Massachusetts General Hospital.

Dr. Peyman Kabolizadeh is joining us at the Memorial Radiation Oncology Medical Group from Oakland University William Beaumont School of Medicine. At Oakland University, he was the director of the Beaumont Proton Therapy Center, Proton Therapy fellowship program director, and also the associate director of radiation oncology residency program. Additionally, he was the chair of gastrointestinal and sarcoma tumor boards, and a member of both the Wayne County Medical Society delegate body and Wayne County Committee on Legislation and Community Affairs.

---

Publications:

1. Qu Y., Harris A, Hegmans A., Petz A., Kabolizadeh P., Penazova H., Farrell N. Synthesis and DNA conformational changes of non-covalent polynuclear platinum complexes. Journal of Inorganic Chemistry, 2004;98(10): 1591-1598.
2. KabolizadehP.,RyanJ.,FarrellN.Differencesinthecellularresponseandsignalingpathwaysof cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis. Biochemical Pharmacology, 2007;73(9): 1270-1279.
3. MitchellC.,KabolizadehP.,RyanJ.,RobertsJD.,YacoubA.,CurielDT.,FisherPB.,HaganMP., Farrell NP., Grant S., Dent P. Low-dose BBR3610 toxicity in colon cancer cells is p53- independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)- phosphatidyl inositol 3 kinase signaling. Molecular Pharmacology, 2007;72(3): 704-714.
4. Benedetti BT., Paterson EJ., Kabolizadeh P., Martinez A., Kipping R., Farrell NP. Effect of Noncovalent Platinum Drug-protien interaction on Drug Efficacy: Use of Fluorescent Conjugates as Probes for Drug Metabolism. Mol Pharm., 2011;8(3):940-8.
5. Kabolizadeh P., Kubicek GJ, Heron DE., Ferris RL., Gibson MK. The Role of Cetuximab in the Management of Head and Neck Cancers. Expert Opin Biol Ther., 2012;12(4):517-28.
6. Kabolizadeh P., Engelmann BJ., Pullen N., Stewart JK., Ryan JJ., Farrell NP. Platinum Anticancer Agents and Antidepressants: Desipramine Enhances Platinum-Based Cytotoxicity in Human Colon Cancer cells. J Biol Inorg chem., 2012;17(1):123-32.
7. Kennan N., Kabolizadeh P., Kim H, Houser C., Beriwal S. Is There an Advantage to Delivering Breast Boost in the Lateral Decubitus Position? Rad. Onc., 2012; 7:163.
8. Silva H., Frezard F., Paterson E., Kabolizadeh P., Ryan JJ, Farrell NP. Heparin Sulfate Proteoglycan-mediated Entry Pathway for Charged Tri-Platinum Compounds. Differential Cellular Accumulation Mechanisms for Platinum. Mol. Pharm., 2012;9(6):1795-1802.
9. Defoe SG., Beriwal S., Jones H., Rakfal S., Heron DE., Kabolizadeh P., Smith RP., Lalonde R. Concurrent Chemotherapy and Intensity-modulated Radiation Therapy for Anal Carcinoma- Clinical Outcomes in a Large National Cancer Institute-designated Integrated Cancer Center Network. Clin Oncol, 2012;24(6):424-31.

10.Kabolizadeh P., Kalash R., Huq M.S., Greenberger J.S., Heron D.E., Beriwal S. Definistions of Total Lung Volumes in Calculating Parameters Predictive for Radiation Induced-Pneumonitis. Am. J. Clin. Onc., 2013; Epub ahead of print; PMID:24064747.

11.Kabolizadeh P., Fulay S., Beriwal S. Are RTOG Para-aortic Contouring for Pancreatic Neoplasm Applicable to Other Malignancies – Assessment of Nodal Distribution in Gynecological Malignancies. Int. J. Radiat. Oncol. Biol. Phys., 2013;87(1):106-110.

12.DeFoe SG., Kabolizadeh P., Heron DE., Beriwal S. Dosimetric Parameters Predictive of Acute Gastrointestinal Toxicity in Patients with Anal Carcinoma Treated with Concurrent Chemotherapy and Intensity Modulated Radiation Therapy. Oncology, 2013; 85:1-7.

Peyman Kabolizadeh,2019 Page 4

13.Vivas E.X., Wegner R., Conley G., Torok J., Heron D.E., Kabolizadeh P., Burton S., Ozhasoglu C., Quinn A., Hirsch BE. Treatment Outcomes in Patients Treated with Cyberknife Radiosurgery for Vestibular Schwannoma. Otology & Neurotology, 2014;35(1): 162-170.

14.Wegner E., Leeman J., Kabolizadeh P., Rwigema JC., Mintz A., Burton S., Heron DE. Fractionated Stereotactic Radiosurgery for Large Brain Metastases. American Journal of Clinical Oncology, 2015; 38(2):135-9.

15.Ling D., Kabolizadeh P., Heron DE., Ohr JP., Wang H., Johnson J., Kubicek GJ. Incidence of Hospitalizations in Patients with Head and Neck Cancer Treated with Intensity Modulated Radiation Therapy. Head and Neck, 2015; 37(12)1750-5.

16.Kabolizadah P., Aghili M, Balakhanlou, B. A Time for Optimism? – The State of Radiation Oncology in Iran. Int. J. Radiat. Oncol. Biol. Phys. 2016; 94(2):221-7.

17. Ding X., Li X., Zhang M., Kabolizadeh P., Yan D., Stevens C. Spot-Scanning Proton Arc (SPArc) Therapy- The first robust and delivery-efficient spot-scanning proton arc therapy. Int. J. Radiat. Oncol. Biol. Phys. 2016; 96(5):1107-1116.

18. Ling DC., Chapman BV., Kim J., Choby GW., Kabolizadeh P., Clump DA., Ferris RL., Kim S., Beriwal S., Heron DE., Duvvuri U. Oncologic Outcomes and Patient Reported Quality of Life in Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Definitive Transoral Robotic Surgery Versus Definitive Chemoradiation. Orol Oncol. 2016; 61:41-6

19.Kabolizadeh P., Chen Y.L., Liebsch N.J. Hornicek F.J., Schwab J.H., Choy E., Rosenthal D.I., DeLaney T.F. Updated Outcome and Analysis of Tumor response in Mobile Spine and Sacral Chordoma Treated with Definitive High Dose Photon/Proton Radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2017; 97(2):254-262.

20.Ding X., Li X., Qin A., Zhou J., Yan D., Stevens C., Krauss D., Kabolizadeh P. Have we reached proton therapy dosimetric limitations? -A Novel robust, delivery-efficient and continues spot- scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. Acta Oncol. 2017; 34:1-3.

21.Li X, Kabolizadeh P, Zhang J, Yan D, Qin A, Zhou J, Hong Y, Guerrero T, Grills I, Stevens C, Ding X. Spot-Scanning Proton Arc (SPArc) Therapy for Stage III Non-Small-Cell Lung Cancer. Radiation Oncology, 2018;13(1):35.

22.Ding X, Xiaoqiang L, Zhang J, Qin A, Zhou J, Yan D, Chen P, Deraniyagala R, Kabolizadeh P. Defining the role of range shifter in treating bilateral head and neck cancer in the era of Intensity Modulated Proton Therapy (IMPT)?; JACMP, 2018; 19:749-755.

23.Schutt CA, Sargent E, Kabolizadeh P, Grills IS, Jacob J. Proton beam radiation-induced glioblastoma multiforme; J Neurosurg Sci, 2018, (Epub ahead of print), PMID: 29582971.

24.David JM, Gresham G, Jabbour SK, Deek M, Thomassian S, Robertson JM, Newman NB, Herman JM, Osipov A, Kabolizadeh P, Tuli R. Neoadjuvant PET and MRI- based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer; J Gastrointest Oncol 2018;9(4):641-649.

Peyman Kabolizadeh,2019 Page 5

25.Sura K, Ye H, Vu C, Robertson J, Kabolizadeh P.How many lymph nodes are enough? Defining the extent of lymph node dissection in stage I-III gastric cancer using the national cancer database. Gastric Cancer; J Gastrointest Oncol 2018; 9:1168-1175.

26.Ding X, Zhou J, Liu G, Li X, Blas K, Wang Y, Qin A, Chinnaiyan P, Yan D, Grills I, Kabolizadeh P. Improving dosimetric outcome for hippocampus and cochlea sparing whole brain radiotherapy using spot-scanning proton arc therapy. Acta Oncol 2019, 58:483-490.

27.Li X, Liu G, Janssens G, De Wilde O, Bossier V, Lerot X, Pouppez A, Yan D, Stevens C, Kabolizadeh P, Ding X. The first prototype of spot-scanning proton arc treatment delivery. Radiotherapy & Oncology. 2019; 137:130-136.

28.Quin T, Ding X, Li X, Wilson G, Buelow K, Sivananthan A, Thermozier S, Henderson A, Epperly M, Franciola D, Wipf P, Greenberger J, Stevens C, Kabolizadeh P. Amelioration of Muscositis in Proton Therapy of Fanconi Anemia Fanca -/- Mice by JP4-039. In Vivo, 2019:331757-1766.

29.Yue Y, David J, Li Q, Blas KG, Fraass B., Hendifar A, Kabolizadeh P, Tuli R. 18F-FDG PET Predicts Hematologic Toxicity in Locally Advanced Anal Cancer Patients Treated with Chemoradiation. Advances in Radiation Oncology, 2019;4:613-622.

30.Quinn TJ, Almahariq MF, Siddiqui ZA, Thompson AB, Hamstra DA, Kabolizadeh P, Gowans KL, Chen PY. Trimodality therapy for atypical teratoid/rhabdoid tumor is associated with improved overall survival: A surveillance, epidemiology and the results analysis, Pediatric Blood Cancer, 2019 66:e27969.

31.LiuG, Yang J, Nie X, Zhu X, Li X, Zhou J, Kabolizadeh P, Li Q, Quan Hm Ding X. A patients- based statistical model of radiotherapy dose distribution in nasopharyngeal cancer, Dose Response, 2019; 17(4)

32.Liu G, Qin A, Li X, Yan D, Stevens C, Kabolizadeh P, Ding X. Improving the Dosimetric Outcome in Bilateral Head and Neck Cancer (HNC) Treatment Using Spot-Scanning Proton Arc (SPArc) Therapy: A Feasibility Study. Radiat Oncol. 2020, 15(1):21

33.Quinn T, Rajagopalan M, Gill B, Mobed Mehdiabadi S, Kabolizadeh P. Patterns of Care and Outcomes for Adjuvant Treatment of pT3N0 Rectal Cancer Using the National Cancer Database. J Gastrointest Oncology, 2020; 11(1):1-12

34.Liu G, Li X, Zhao L, Zheng W, Qin A, Stevens C, Yan D, Kabolizadeh P, Ding X. A novel energy sequence optimization algorithm for efficient spot-scanning proton arc (SPArc) treatment delivery. Acta Oncologica, 2020; DOI: 10.1080/0284186X.2929.1765415

35.Quinn TJ, Kabolizadeh P. Rectal Cancer in Young Patients: Incidence and Outcome Disparities. J Gastrointest Oncology, 2020; 11(5):880-893

36.Parzen JS, Hartsell W, Chang J, Apisarnthanarax S, Molitoris J, Durci M, Tsai H, Urbanic J, Ashman J, Vargas C, Stevens C, Kabolizadeh P. Hypofractionated Proton Beam Radiotherapy in Patients with Unresectable Liver Tumors: Multi-Institutional Prospective Results from the Proton Collaborative Group, Radiat Oncol. 2020; 15(1):255

Peyman Kabolizadeh,2019 Page 6

37.Chang S, Liu G, Zhao L, Dilworth JT, Zheng W, Jawad S, Yan D, Chen P, Stevens C, Kabolizadeh P, Li X, Ding X, Feasibility Study: Spot-Scanning Proton Arc Therapy (SPArc) for Left-sided Whole Breast Radiotherapy, Radiat Oncol, 2020; 15(1):232

38.Grzywacz V, Guinn TJ, Wilson T, Reiemeier P, Navin M, Hamstra D, Anderson J, Chinnaiyan P, Stevens C, Kabolizadeh P. Ethical Allocation of Proton Therapy and the Insurance Review Process, Pract Radiat Oncol. 2021; 3:S1879-8500, Online ahead of print.

39.Prazen JS, Vayntraub A, Squires B, Almahariq MF, Thompson AB, Robertson JM, Kabolizadeh P, Quinn TJ. A population-based Analysis of Chemoradiation versus Radiation Aline in the Definitive Treatment of Patients with Stage I-II Squamous Cell Carcinoma of the Anus, J Gastrointest Oncol. 2021; 12(2): 831-844.

40.Rehman R, Squires B, Osto M, Quinn T, Kabolizadeh P. Hidradenocarcinoma of the Abdominal Wall Treated With Wide Surgical Excision and Adjuvant Radiotherapy, Cureus, 2021; 13(4):e14724.

41.Parzen J, Zhen W, Li X, Ding X, Kabolizadeh P. Optimization of Field Design in the Treatment of Rectal Cancer with Intensity Modulated Proton Beam Radiotherapy: How Many Fields Are Needed to Account for Rectal Distension Uncertainty?, Advances in Rad Onc., 2021; Accepted

42.Parzen L, Choung M, Chang J, Rosen L, Urbanic J, Hartsell W, Tsai H, Sinesi C, Zeng J, Mishra M, Vargas C, Stevens C, Kabolizadeh P. Dosimetry and Toxicity Profile of Patients with Esophageal Cancer Treated with Proton Beam Radiotherapy: Outcomes from the Proton Collaborative Group REG001-09 Trial, Advances in Rad Onc., 2021; Accepted.